Technical Analysis for JAZZ - Jazz Pharmaceuticals plc

Grade Last Price % Change Price Change
grade D 125.92 -1.96% -2.52
JAZZ closed down 1.96 percent on Monday, April 22, 2019, on 72 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical JAZZ trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -1.96%
Doji - Bullish? Reversal -1.96%
Below Lower BB Weakness -1.96%
Oversold Stochastic Weakness -1.96%
Fell Below 50 DMA Bearish -1.38%
Expansion Pivot Sell Setup Bearish Swing Setup -1.38%

Older signals for JAZZ ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.
Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Pain Drugs Imaging Pharmaceutical Products Prostate Cancer Lymphoma Pharmacokinetics Transplantation Movement Disorders Obsessive Compulsive Disorder Severe Chronic Pain Acute Lymphoblastic Leukemia Oral Hygiene Pegylation Asparaginase Host Diseases Narcolepsy
Is JAZZ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 184.0
52 Week Low 113.52
Average Volume 670,743
200-Day Moving Average 149.2984
50-Day Moving Average 134.1892
20-Day Moving Average 138.143
10-Day Moving Average 135.794
Average True Range 3.7596
ADX 19.99
+DI 17.0908
-DI 29.9756
Chandelier Exit (Long, 3 ATRs ) 133.6612
Chandelier Exit (Short, 3 ATRs ) 136.6988
Upper Bollinger Band 148.4615
Lower Bollinger Band 127.8245
Percent B (%b) -0.09
BandWidth 14.938868
MACD Line -1.39
MACD Signal Line 0.6304
MACD Histogram -2.0204
Fundamentals Value
Market Cap 7.57 Billion
Num Shares 60.1 Million
EPS 6.49
Price-to-Earnings (P/E) Ratio 19.40
Price-to-Sales 5.40
Price-to-Book 3.78
PEG Ratio 0.72
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 131.16
Resistance 3 (R3) 131.57 130.24 130.28
Resistance 2 (R2) 130.24 128.91 130.03 129.99
Resistance 1 (R1) 128.08 128.08 127.42 127.67 129.70
Pivot Point 126.75 126.75 126.42 126.54 126.75
Support 1 (S1) 124.59 125.42 123.93 124.18 122.14
Support 2 (S2) 123.26 124.59 123.05 121.85
Support 3 (S3) 121.10 123.26 121.56
Support 4 (S4) 120.69